Compare VET & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | VERA |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | VET | VERA |
|---|---|---|
| Price | $8.40 | $50.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $67.67 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,445,514,003.00 | N/A |
| Revenue This Year | $9.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.48 | N/A |
| 52 Week Low | $5.14 | $18.53 |
| 52 Week High | $10.49 | $50.16 |
| Indicator | VET | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 83.76 |
| Support Level | $8.54 | $40.38 |
| Resistance Level | $9.28 | $47.10 |
| Average True Range (ATR) | 0.36 | 3.45 |
| MACD | -0.10 | 1.31 |
| Stochastic Oscillator | 10.43 | 95.40 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.